WHOOP's Ulta Beauty deal puts a disputed health feature on the shelf.

WHOOP is leaving the gym aisle for the beauty counter

WHOOP and Ulta Beauty announced on November 3, 2026 that the fitness wearable will go on sale at select Ulta stores and on Ulta.com starting in March 2027, putting WHOOP 5.0 and WHOOP MG, plus an exclusive line of bands and accessories, in front of Ulta's 47 million loyalty members. Kyle Leahy, WHOOP's chief commercial officer, called it "an exciting opportunity to introduce WHOOP to millions of new consumers" and said he expects "the beginning of a much broader relationship" between the two companies.

That reach is the real story here, more than the shelf space. WHOOP has spent more than a decade selling mostly to athletes and the recovery-obsessed, through its own site and a handful of sporting goods retailers. Ulta's customer base skims makeup aisles and skincare shelves, plenty of whom have never considered an always-on wearable with a monthly subscription attached. Putting WHOOP next to serums and body oil is a bet that wellness spending habits, not athletic ones, will sell the device.

What the deal actually covers

The announcement is narrower than it might sound. It is a retail distribution agreement, not an acquisition or an equity stake. Ulta will stock the WHOOP 5.0 and WHOOP MG bands, along with accessories made for the partnership, in select stores and online starting next spring. Neither company has detailed pricing, store counts, or whether WHOOP's membership fees will ever connect to Ulta's rewards program, something outside analysts have floated but neither company has confirmed. [[INLINE]]

For WHOOP, the timing lines up with a run of momentum. The company raised $575 million in a Series G round in March 2026 at a $10.1 billion valuation, nearly tripling its 2021 figure, with Collaborative Fund leading and Qatar Investment Authority, Mubadala and Abbott participating. WHOOP said bookings grew 103% year over year in 2025 and that it was cash-flow positive, numbers that read as a company positioning for an IPO rather than one scrambling for distribution.

What's actually inside WHOOP MG

The device doing the heavy lifting in this pitch, WHOOP MG, carries two headline features beyond standard sleep and recovery tracking: an on-demand ECG and Blood Pressure Insights, which estimates systolic and diastolic readings from heart rate, heart rate variability and blood flow patterns gathered overnight. Only one of those two is FDA cleared. The ECG received FDA 510(k) clearance in April 2025 for detecting atrial fibrillation and irregular heart rhythm, a genuine medical-device authorization.

Blood Pressure Insights is a different story, and it's the one worth knowing before anyone buys this at a beauty counter expecting a clinical reading.

The dispute the press release leaves out

In July 2025, the FDA sent WHOOP founder Will Ahmed a warning letter stating that Blood Pressure Insights was being marketed as an unauthorized medical device, arguing that blood pressure estimation was not a low-risk function and couldn't qualify as a general wellness feature. WHOOP pushed back publicly, saying the agency was overstepping its authority, and pointed to its own validation work training the model on more than 32,000 sleep sessions from over 11,000 members.

The standoff shifted in 2026. The FDA updated its general wellness guidance in January, concluding that optical blood pressure sensing doesn't need device regulation when it's framed strictly as wellness information with no medical-grade accuracy claims. By June, the agency told WHOOP it would not enforce device requirements against the modified feature, and Ahmed announced on LinkedIn that the warning letter had been formally closed. That is a regulatory truce, not a clearance. The FDA's closure applies only to the modified BPI as it currently exists, and the agency has never authorized or validated its accuracy the way it did WHOOP's ECG. WHOOP's own disclaimers still say the feature cannot diagnose or manage any condition and isn't intended for pregnant users or anyone on blood pressure medication.

Why Ulta wants this too

Ulta isn't just renting shelf space to a trendy gadget. The retailer has been building out wellness shop-in-shop sections, already running in roughly 370 stores with more planned, as it looks to diversify beyond color cosmetics into a market where self-care and health tracking increasingly overlap. WHOOP gives Ulta a recognizable, high-profile name to anchor that push, and a reason for its wellness-first shoppers, not just its beauty-first ones, to keep coming back. For a reader weighing whether to care about WHOOP's wearables versus competitors in the broader wearables category, the Ulta deal changes where you'll encounter the device, not what it can actually tell you about your body.

Our take

The Ulta partnership is a smart distribution move and a sign of where wellness retail is heading, nothing more sinister than that. But it lands at the same moment WHOOP's most medically styled feature is still operating on a regulatory technicality rather than a genuine clearance. Buy WHOOP for what its hardware reliably does well: tracking sleep, heart rate and recovery trends over time. Don't let a beauty store aisle convince you its blood pressure number belongs in a chart at your doctor's office.

Health Trend Wire holds no position in WHOOP and was not paid for this article. This is general information, not medical or financial advice.